• Publications
  • Influence
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
OBJECTIVE This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in theExpand
  • 292
  • 12
Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
Sertindole is an atypical antipsychotic that is efficacious in schizophrenia and is associated infrequently with extrapyramidal symptoms (EPS). This study assessed time to treatment failure with 24Expand
  • 77
  • 6
Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐controlled
Motilin‐receptor agonists are prokinetics; whether they relieve the symptoms of functional dyspepsia is unknown. We aimed to test the efficacy of the motilin agonist ABT‐229 in functional dyspepsiaExpand
  • 219
  • 3
Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial
INTRODUCTION Erythromycin, a motilin agonist, is a potent prokinetic. ABT-229 is a specific motilin agonist that dose dependently accelerates gastric emptying. Dyspepsia and gastroparesis are commonExpand
  • 162
  • 2
Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning.
It is recognized that testosterone (T) levels decrease in men with age, as does sexual function. We hypothesize that T supplementation in hypogonadal men with sexual dysfunction will restore certainExpand
  • 97
  • 2
  • PDF
Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety
Evidence from clinical trials supports the claim that sertindole is a potent antipsychotic drug at a dose of 12–24 mg/day. Its action against positive symptoms is as potent as that of the traditionalExpand
  • 38
  • 2
Pharmacokinetics of sertindole in healthy young and elderly male and female subjects
The pharmacokinetic disposition of oral sertindole, a new selective antipsychotic compound, in young and elderly male and female subjects was investigated.
  • 33
  • 1
EFFECTS OF FOOD, ANTACID, AND DOSAGE FORM ON THE PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF SERTINDOLE IN HEALTHY VOLUNTEERS
The pharmacokinetic disposition and relative bioavailability of sertindole administered as a tablet dosage form under fasting conditions, in the presence of food, in the presence of antacid, and asExpand
  • 23
  • 1
Efficacy of a motilin receptor agonist (ABT‐229) for the treatment of gastro‐oesophageal reflux disease
ABT‐229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats.
  • 16
D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects
Acute extrapyramidal syndromes (EPS) are frequently recorded during treatment with classical neuroleptic drugs. In patients with EPS a consistent finding is high central D,-receptor occupancy ( >Expand
  • 25
...
1
2
3
4
5
...